It is really more a question of what coming out on top looks like. A not so great deal for the whole B franchise because poor bargaining power? P2b failure? K dropped? Then what will the ultimate share sale price be? Or ramping up of subsequent B products, developing oral formulation for IBD, cream for eczema, or eye/ear stuff...Or outright failure to get a deal. Very hard to know, really, still.